Company
Novocure
Nasdaq: NVCR
Global oncology company headquartered in Baar, Switzerland, founded in 2000; makes Tumor Treating Fields devices branded Optune, approved for glioblastoma, mesothelioma, lung and now pancreatic cancer.
2 stories
Regulatory News has published 2 stories about Novocure on 8 October 2026, each sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 8 October 2026.
This page is generated from Regulatory News’ editorial coverage of Novocure. It is not an advertisement.
On the record
- Company
- Novocure Limited (Nasdaq: NVCR)
- Headquarters
- Baar, Switzerland
- Founded
- 2000, Haifa, Israel — by Technion biophysicist Yoram Palti
- Regulator
- Japan's Ministry of Health, Labour and Welfare (MHLW)
- Latest milestone
- MHLW (Japan) approval, Optune Pax for pancreatic cancer
Each line is taken from the most recent story of ours that states it.
